Elan has reported a 17 per cent rise in revenues for the first quarter of the year.
Revenues at the firm that focuses on neurological disorders totalled $288.4 million in the three months, Elan said.
Revenue from its multiple sclerosis drug Tysabri totalled $288.2 million, which was just ahead of expectations according to Bloomberg News.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team